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TRIB2, a serine/threonine pseudokinase identified as an oncogene, is expressed at high levels in the T-cell compartment
of hematopoiesis. The proliferation of developing thymocytes is tightly controlled to prevent leukemic transformation of
T cells. Here we examine Trib2 loss in murine hematopoiesis under steady state and proliferative stress conditions, including
genotoxic and oncogenic stress. Trib2−/− developing thymocytes show increased proliferation, and Trib2−/− mice have
significantly higher thymic cellularity at steady state. During stress hematopoiesis, Trib2−/− developing thymocytes undergo
accelerated proliferation and demonstrate hypersensitivity to 5-fluorouracil (5-FU)-induced cell death. Despite the
increased cell death post 5-FU-induced proliferative stress, Trib2−/− mice exhibit accelerated thymopoietic recovery post
treatment due to increased cell division kinetics of developing thymocytes. The increased proliferation in Trib2−/−
thymocytes was exacerbated under oncogenic stress. In an experimental murine T-cell acute lymphoblastic leukemia
(T-ALL) model, Trib2−/− mice had reduced latency in vivo, which associated with impaired MAP kinase (MAPK)
activation. High and low expression levels of Trib2 correlate with immature and mature subtypes of human T-ALL,
respectively, and associate with MAPK. Thus, TRIB2 emerges as a novel regulator of thymocyte cellular proliferation,
important for the thymopoietic response to genotoxic and oncogenic stress, and possessing tumor suppressor function.
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Introduction
TRIB2 is a member of the mammalian Tribbles
family of serine/threonine pseudokinases (TRIB1–3).
Studies focused on the pathological role of TRIB2 in
various disease states, including hematological malig-
nancy, solid tumors, autoimmune and inflammatory
diseases, have identified TRIB2 as a critical signaling
modulator and mediator [1]. However, it is unclear if
this is true in a physiological context where regulation
of diverse signaling pathways is cell type and
developmental stage dependent. Studies of Tribbles
orthologues in Xenopus [2] and Drosophila [3–5]
highlight an evolutionary conserved role for Tribbles in
the regulation of normal cellular proliferation. In these
organisms, Tribbles coordinates cell division and
morphogenesis to ensure proper organ development.
In Drosophila, Tribbles ensuring mitosis occurs in a
timely manner by regulating String/CDC25 turnover at
protein level [3–5]. Histological study of a Trib2
knockout mouse model showed no phenotypic defects
in various organs during embryogenesis [6]. These data
suggest TRIB2 function is required for proper cellular
behavior rather than tissue organization.
In hematological malignancies, TRIB2 has been
implicated in acute myeloid leukemia (AML), as well
as T-cell acute lymphoblastic leukemia (T-ALL).
Enforced expression of Trib2 by retroviral transduction
induces potent murine AML [7] and Trib2 is a target
gene of MEIS1 [8] in HOX-induced murine leukemia.
In human AML, elevated expression of Trib2 was
shown to be driven by the transcription factors
E2F1 [9] and NOTCH1 [10] where the latter was found
to be aberrantly activated in an AML subset that has a
mixed myeloid/T-lymphoid phenotype [10]. In human
T-ALL, high Trib2 expression was found to be
associated with activated NOTCH1 signaling [11].
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Indeed, Trib2 was also identified as a downstream
target of PITX1 [12] and TAL1 [13], transcription
factors that are also aberrantly expressed in T-ALL.
These oncogenic transcription factors involved in
TRIB2 regulation and associated AML and T-ALL
are important players in lineage specification during
normal hematopoiesis [14–18 ], suggesting a potential
role for TRIB2 in normal hematopoiesis.
We previously showed that Trib2 expression is
highest in the T-cell lineage in normal hematopoiesis
and is regulated during αβ T-cell development in the
thymus [19]. The thymus is a lymphoid organ where
progenitors from the bone marrow (BM) commit
to T-cell lineage development, differentiate into
functional naive T cells, and are then exported to the
periphery as part of the adaptive immune system. Here
we show that TRIB2 is a novel cell cycle brake essential
for balanced proliferation of developing murine
thymocytes. Loss of TRIB2 causes developing thy-
mocytes to be highly proliferative but with heightened
sensitivity to in vivo genotoxic drug treatment. As such,
Trib2 ablation accelerates thymopoietic recovery
following genotoxic insult. However, in cells expressing
a T-cell oncogene, the absence of TRIB2 led to
enhanced T-cell leukemic transformation associated
with impaired MAP kinase (MAPK) signaling. In the
human disease, low levels of Trib2 expression correlate
with a mature T-ALL phenotype and high levels of
expression with an immature phenotype. In accordance
with our experimental model, MAPK signaling
correlates with Trib2 expression in T-ALL.
Results
TRIB2 is dispensable for murine hematopoiesis in the
bone marrow
To investigate whether TRIB2 has a role in normal
hematopoiesis, we examined the hematopoietic system
of a Trib2 knockout mouse model (129S5-Trib2tm1Lex,
referred as Trib2−/− hereafter) where the coding and
noncoding regions of exon 1 were disrupted and
thus enabled Trib2 genotyping by PCR analysis
(Supplementary Figure S1; Supplementary Table S1).
Compared with wild-type (WT) mice, Trib2−/− mice
had similar red blood cell and white blood cell differ-
ential counts, except for the platelet count which was
significantly higher but within the normal physiological
range (Figure 1a and b). In addition, no difference was
found between WT and Trib2−/− mice in the distribu-
tion of mature myeloid, B and T-cells in the blood
(Figure 1c). These data indicate that loss of TRIB2
does not affect terminal differentiation and production
of mature blood cells of different lineages. We
next studied the BM, the primary site of adult
hematopoiesis, to determine whether TRIB2 influences
hematopoietic cell fate choice at an earlier stage.
Trib2−/− mice had similar BM cellularity compared with
WT mice (Figure 1d). No difference was found in the
frequency of circulating CD4+ and CD8+ T-cells, lineage
committed Gr-1+/CD11b+ myeloid cells and CD19+
/B220+ B-lymphoid cells (Figure 1e). Moving up the
hematopoietic hierarchy, Trib2−/− mice had similar fre-
quencies of hematopoietic stem and progenitor cells
(HSPCs), including multipotent progenitors, common
lymphoid progenitors, granulocyte-macrophage pro-
genitors, megakaryocyte-erythroid progenitors, com-
mon lymphoid progenitors and hematopoietic stem
cells (HSCs) compared with WT mice (Figure 1f and
g). Hence, TRIB2 is not essential for hematopoietic cell
fate choice as loss of TRIB2 did not lead to skewing of
hematopoietic cell differentiation. Thus, at steady
state, Trib2 ablation does not affect the hierarchical
organization of the murine hematopoietic system.
We next assessed the repopulating capability
and multi-lineage differentiation potential of Trib2−/−
HSPCs by transplantation of CD45.2+ whole-BM-
nucleated cells (WT or Trib2−/− donor) into lethally
irradiated CD45.1+ mice (recipients). TRIB2 loss did
not affect long-term engraftment of donor cells and
their capability to fully reconstitute the blood system of
recipients (Supplementary Figure S2A–C). Analysis
of blood collected periodically from recipients
showed no skewing of differentiation into myeloid
and lymphoid lineages in the absence of TRIB2
during hematopoietic reconstitution (Supplementary
Figure S2D). No significant difference was found in
the HSPC populations in recipients transplanted with
either genotype (Supplementary Figure S2E and F).
We conclude that TRIB2 is dispensable for the
maintenance of the hematopoietic system through dif-
ferentiating HSPC populations that reside in the BM.
TRIB2 regulates the proliferation of developing
thymocytes
T-cell development takes place in the thymus that is
seeded constantly by T-cell progenitors originating in
the BM. We found that Trib2−/− mice had statistically
significant higher thymic cellularity compared with
WT mice (Figure 2a). This suggests dysregulation of
thymopoiesis in the absence of TRIB2. We further
examined thymic subsets along the αβ T-lineage
developmental pathway by immunophenotyping.
Non-T-lineage markers (CD11c, Gr-1, B220, Ter119
and NK1.1) were included in all the experimental
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analysis to exclude cells of other lineages present in
thymus. Gating for lineage markers, including CD4
and CD8, were adjusted so as not to exclude c-Kit+
thymic progenitors that express low cell surface levels
of lineage markers when defining immature CD4−CD8−
double-negative (DN) thymocytes [20] (Supplementary
Figure S3). For gating of thymic subsets, DN3
thymocytes (LinloCD44−CD25+) were divided further
into DN3E (expected: FSC
lo) and DN3L (larger: FSC
hi)
subsets, based on cell size [21]. This is equivalent to
characterization of DN3 into DN3a and DN3b
subsets, based on CD27 marker, that corresponded to
pre- and post-β selection [22]. Similarly, CD4+CD8+
double-positive (DP) thymocytes were divided further
into DPsm (small resting: FSC
lo) and DPbl (blasts:
FSChi) subsets [23]. As described [21, 24, 25], we found
that DN3E and DPsm subsets were not proliferative as
499% were in G0/G1 phase and only 10–20% were
CD71+. In contrast, DN3L and DPbl subsets were
actively cycling as 60–70% were in S–G2/M phases
and 90% were CD71+ (Supplementary Figure S4A–C).
Our analysis of the thymic subsets showed that, in
Figure 1 TRIB2 loss does not affect murine hematopoiesis in bone marrow. Complete blood counts (a) and WBC differential
counts (b) of WT (n = 13) and Trib2−/− (n = 22) mice were determined by hematology analyzer. BA, basophils; EO, eosinophils;
LY, lymphocytes; MO, monocytes; NE, neutrophils. (c) The distribution of mature myeloid, B and T-cells in the blood of WT (n = 3)
and Trib2−/− (n = 10) mice were measured by flow cytometry using the indicated lineage specific cell surface markers. (d) BM
cellularity (n = 5–7 per genotype) was counted by trypan blue exclusion after RBC lysis of the cell suspension collected from two
pelvises, femurs and tibias. (e) The distribution of myeloid, B and circulating T-cells in the BM of WT (n = 3) and Trib2−/− (n = 9)
mice. (f) Immunophenotyping of HSPCs populations (HSC, MPP, CMP, GMP, MEP and CLP) in BM. Each sub-population is
indicated in the outlined areas (top row). The corresponding values in the representative staining profile of WT (middle row) and
Trib2−/− (bottom row) mice (n = 3 per genotype) are frequency of BM and graphed in g. CLP, Lin−IL-7Rα+; CMP, LK CD34+
CD16/32lo; GMP, LK CD34+CD16/32hi; HSC, LSK CD150+CD48−; Lin, lineage; LK, Lin−c-Kit+; LSK, Lin−Sca-1+c-Kit+; MPP, LSK
CD150−CD48−; MEP, LK CD34−CD16/32−; SSC-H, side scatter-height. For a, unpaired Student’s t-test was used for statistical
analysis. *Po0.05, all quantified data are presented as mean and s.e.m. CMP, common myeloid progenitor;
CLP, common lymphoid progenitor; GMP, granulocyte-macrophage progenitor; MEP, megakaryocyte-erythroid progenitor;
MPP, multipotent progenitor; RBC, red blood cell; WBC, white blood cell.
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general, Trib2−/− mice had a lower frequency of
immature DN1–4 subsets, but the mature DP and
single-positive subsets were unaffected compared with
WT mice (Figure 2b and c). The higher cellularity of
Trib2−/− thymus was due to the significant increase of
mature subsets (DPsm and CD4 single positive) but not
Figure 2 TRIB2 regulates the homeostasis of intrathymic T-cell development. (a) Thymic cellularity of WT (n = 31) and Trib2−/−
(n = 21) mice was counted by trypan blue exclusion after RBC lysis. (b) Flow cytometry of thymic subsets. The complete gating
strategy is provided in Supplementary Figure S3. Each subset is indicated in the outlined areas (top row). The corresponded
values in the representative staining profile of WT (middle row) and Trib2−/− (bottom row) mice are frequency of thymus and
graphed in c. CD4 SP, CD4+CD8−; CD8 SP, CD4−CD8+; DN1, LinloCD44+CD25−; DN2, LinloCD44+CD25+; DN3E, Lin
loCD44−
CD25+FSClo; DN3L, Lin
loCD44−CD25+FSChi; DN4, LinloCD44−CD25−; DPbl, CD4
+CD8+FSChi; DPsm, CD4
+CD8+FSClo; FSC-A,
forward scatter-area; SSC-A, side scatter-area. (d) Number of cells for each subset. (e) Further characterization of DN1 cells
based on c-Kit surface expression. hi, high; lo, low; Neg, negative. DN1 subsets were graphed in frequency of thymus (f) and cell
number (g). For c, d, f and g, n = 7–8 per genotype. (h) Basal level of apoptosis of each thymic subset (n = 3 per genotype) was
determined by the surface expression of Annexin V after exclusion of DAPI-stained dead cells. (i) Intracellular level of Ki-67
across thymic subsets (n = 4–5 per genotype) was measured by flow cytometry (left). An overlap of histogram (right) showed
Trib2−/− DN1 cells had higher level of Ki-67 compared with that of WT. FMO, Fluorescence Minus One; Norm, normalized.
For statistical analyses, unpaired Student’s t-test was used for a, i, and two-way ANOVA was used for c, d and f. **Po0.01;
***Po0.001, all quantified data are presented as mean and s.e.m. ANOVA, analysis of variance; DAPI, 40, 6-diamidino-2-
phenylindole; RBC, red blood cell; SP, single positive.
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the immature DN1–4 subsets (Figure 2d). The DN1
(LinloCD44+CD25−) subset is heterogeneous and
divided into DN1a–e subsets based on CD24 and c-Kit
surface expression [26]. Here the DN1 subset was divi-
ded broadly into c-Kithi (DN1a/b), c-Kitlo (DN1c) and
c-Kit− (DN1d/e) subsets (Figure 2e). Trib2−/− c-Kit−
DN1 progenitors were present at a significantly lower
frequency but had similar cell numbers compared with
WT mice (Figure 2f and g). To rule out the possibility
that lower frequency of Trib2−/− DN1–4 subsets were
due to increased apoptosis, we measured Annexin V
expression and showed no difference between the two
genotypes (Figure 2h). As Trib2−/− mice had higher
numbers of mature subsets that must be derived from
immature subsets, we hypothesized that immature thy-
mocytes were cycling faster and gave rise to more
mature differentiated thymocytes in the absence of
TRIB2. Ki-67 is a proliferation marker, expressed by
cells in active cell cycle (G1–S–G2/M) but not by resting
cells in G0 [27]. Indeed, intracellular staining of Ki-67
showed that Trib2−/−DN1, DN2 and DN3E subsets had
significantly higher levels of Ki-67 compared with WT
thymic subsets (Figure 2i), indicating that more Trib2−/−
developing thymocytes are in cycling state. This does not
result in T-cell accumulation outside the thymus how-
ever (Supplementary Figure S5).
Cell cycle regulation is crucial for proper T-cell
development. DN3 thymocytes must be briefly arrested
(DN3E) at the G0/G1 cell cycle phases to allow
V(D)J recombination to take place at the Tcrb locus,
initiated by the RAG proteins [28, 29]. Functional
Tcrb rearrangements lead to formation of pre-T-cell
receptors where the signals drive the subsequent
development of thymocytes to early DP stage. Given
that Trib2−/− developing thymocytes proliferate faster,
we determined whether the loss of TRIB2 affects the
cell cycle status of these subsets and Tcrb rearrange-
ments. DNA staining showed that Trib2−/− thymocytes
at each stage of the T-cell development had a
similar cell cycle profile compared with WT mice
(Supplementary Figure S4A and B). This suggests
that TRIB2 does not regulate the cell cycle phase
progression, and that the increased cycling of Trib2−/−
developing thymocytes is likely due to changes in
cell division kinetics at the steady state. Importantly,
Trib2−/− DN3E thymocytes were arrested at G0/G1
phases such as WT DN3E thymocytes. As such,
analysis of Tcrb rearrangement involving the Jβ2.1
to Jβ2.7 gene segments demonstrated that Trib2−/−
thymocytes contain polyclonal Tcrb rearrangements
similar toWT thymocytes (Supplementary Figure S4D).
Trib2−/− thymocytes are hypersensitive to 5-fluorouracil-
induced cell death
5-fluorouracil (5-FU) is a standard chemotherapeutic
drug widely used to treat cancers, as it targets
rapidly cycling cells. Misincorporation of 5-FU meta-
bolite into DNA during DNA replication initiates futile
cycles of DNA excision, repair and further mis-
incorporation that eventually lead to DNA strand
breaks and cell death [30]. On account of that, we
hypothesized that Trib2−/− developing thymocytes which
are highly proliferative to be more sensitive to 5-FU
compared with WT thymocytes [31]. We performed a
time-course study of in vivo 5-FU treatment. Trib2−/−
mice had significantly higher total thymic cellularity at
steady state (Figure 2a); however, the significance dif-
ference lost at 16 and 24 h post treatment (Figure 3a).
Significant increase of cell death (late apoptotic) was
found in Trib2−/− thymic cells at 24 h post treatment
(Figure 3b and c). Notably, we demonstrated that DN3L
and DPbl subsets, which are known to be proliferative
(Supplementary Figure S4A–C), were significantly
reduced in Trib2−/− mice 16 h post treatment. DN3E and
DPsm subsets, which were in resting state, were unaf-
fected in treated WT and Trib2−/− mice. Unexpectedly,
Trib2−/− c-Kithi DN1 thymic progenitors were also sig-
nificantly reduced after 16 h of exposure to 5-FU,
whereas Trib2−/− c-Kit− and c-Kitlo DN1 progenitors
were unaffected like WT mice (Figure 3d and e). c-Kithi
DN1 progenitors were shown previously to exclusively
exhibit a proliferative burst capacity by OP9-DL1 co-
culture system compared with c-Kit− and c-Kitlo DN1
progenitors [26]. Interestingly, 5-FUwas shown recently
to preferentially induce apoptosis in c-Kithi HSCs that
have rapid cell division kinetics compared with c-Kitlo
HSCs in vitro [32]. Overall, these data confirmed a role
for TRIB2 in controlling the cell division kinetics of
thymocytes and hence their enhanced sensitivity to 5-
FU genotoxic drug.
Acceleration of thymopoietic recovery in the absence of
TRIB2 after genotoxic insult
Previous studies on the response of thymus to
5-FU-mediated genotoxic insult have shown that
5-FU induces apoptosis of thymocytes, thymic weight
loss and damages to thymic architecture that is crucial
for T-cell development [33, 34]. Thymic inner archi-
tecture exhibited morphological recovery on day 7 and
was back to normal on day 10 post 5-FU injury in
previous work. However, little is known about
thymopoietic restoration. We compared thymopoietic
recovery of WT and Trib2−/−mice 4 and 14 days after a
single dose of 5-FU administration. Trib2−/− mice had
KaiLing Liang et al.
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higher thymic cellularity compared with WT mice at
4 and 14 days post treatment and the thymus was
relatively bigger at 14 days post treatment (Figure 4a
and b). Importantly, the higher cell count was not due
to the increase of myeloid and B cells that do not
normally develop in thymus (Figure 4c). Although WT
and Trib2−/− mice both had the hierarchy of thymic
subsets restored to normal on day 14 compared
with day 4 post 5-FU treatment (Supplementary
Figure S6A–C), Trib2−/− mice had significantly higher
numbers of DN1 progenitors and the subsequent
mature subsets (Figure 4d). This indicates that Trib2−/−
mice had accelerated thymopoietic recovery. At steady
state, thymopoiesis is sustained mainly by c-Kithi DN1
progenitors [35]. However, these progenitors were
absent inWT and Trib2−/− thymus from day 1 to day 14
post 5-FU treatment (Supplementary Figure S6D).
Instead, we found a significant increase of c-Kit− DN1
progenitors in Trib2−/− thymus suggesting expansion of
these progenitors drives the accelerated recovery
(Figure 4e).
We postulated that the acceleration of thymopoietic
recovery in the absence of TRIB2 is due to the intrinsic
highly proliferative nature of Trib2−/− thymocytes. In
developing thymocytes, proliferation and differentia-
tion are tightly linked. Analysis of Tcrb rearrange-
ments for the joining of Dβ2 to Jβ2 gene segments
showed less immature thymocytes that have not
undergone Tcrb rearrangements (germline (GL) band)
present in Trib2−/− thymus compared with WT thymus
14 days post 5-FU treatment (Figure 4f). This supports
our finding that thymopoiesis was more active in
treated Trib2−/−mice. We further assessed the quiescent
state of DN thymocytes through dual staining of DNA
and Ki-67. Compared with WT DN thymocytes, sig-
nificantly less Trib2−/− thymocytes in DN1 and DN4
subsets were resting (G0) and correspondingly more
Trib2−/− thymocytes in these subsets were in cycling
state (G1–S/G2–M; Figure 4g and h). This indicates
that TRIB2 regulates the cell cycle entry of thymocytes.
To expand beyond a static assessment of proliferation,
we did time-course experiments of in vivo
Figure 3 Trib2−/− thymocytes are more susceptible to 5-FU-induced cell death. (a) Mice were treated with 5-FU (250 mg kg1, i.p.)
and sacrificed after 16 and 24 h to determine the thymic cellularity. (b) Apoptosis assays were performed to determine the fraction
of living, early and late apoptotic cells in thymus at 16 and 24 h post treatment. (c) A representative staining profile (b) of
5-FU-treated WT and Trib2−/− thymus. Living, DAPI−AV−; early apoptotic, DAPI−AV+; late apoptotic, DAPI+AV+. The values
indicated in the outlined areas are frequency of thymus. (d) The cellularity of thymic subsets at 16 h post treatment. (e) Overlay of
the histograms of DN1 and DN3 cells for c-Kit expression and FSC-A signals, respectively, showed loss of Trib2−/− DN1c-Kit+ and
DN3L cells at 16 h post treatment. For a, b and d, n = 5 per genotype per studied time point. For statistical analyses, unpaired
Student’s t-test was used for a and two-way ANOVA was used for b, d. *Po0.05; **Po0.01, all quantified data are presented as
mean and s.e.m. ANOVA, analysis of variance; DAPI, 4’, 6-diamidino-2-phenylindole; i.p., intraperitoneal.
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Figure 4 Thymopoietic recovery is accelerated in the absence of TRIB2 after genotoxic stress. (a) Thymic cellularity of mice after
4 and 14 days of 5-FU treatment. (b) The white arrow indicates representative thymus of the dissected WT and Trib2−/−mice.
(c) The cellularity of non-T-lineage cells (DC, CD11c+; NK cells, Nk1.1+; B, CD19+B220+; Myeloid, Gr-1+CD11b+) in thymus (n = 3
per genotype) were determined by flow cytometry. Cellularity for thymic subsets (d) and DN1 subsets (e). (f) PCR analysis (n = 3
per genotype) of Tcrb rearrangement involving the Dβ2 to Jβ2 gene segments. GL denotes the position of the germline PCR
product and number indicates the different rearrangements. 1 kb M, 1 kb DNA marker; neg ctrl, no template negative control.
(g) Flow cytometry to determine the fraction of developing thymocytes in resting (G0) and active (G1–S/G2/M) cell cycle. Each
phase is indicated in the outlined areas (top row). The corresponding values in the representative staining profile of WT (middle
row) and Trib2−/− (bottom row) mice (n = 2–3 per genotype) are frequency of each phase and graphed in h. (i) The frequency of
BrdU uptake by DN3 thymocytes after 1 and 4 h of pulsing. A representative staining profile of WT and Trib2−/− mice (n = 3 per
genotype per studied time point) is shown here. The values indicated in the outlined areas are the frequencies of BrdU+ DN3
thymocytes and graphed in j. For a, d and e, n = 9 per genotype per studied time point. 5-FU dosage for a–e was 250 mg kg− 1,
whereas for f–j it was 200 mg kg− 1. For statistical analyses, unpaired Student’s t-test was used for a and two-way ANOVA was
used for c–e, h and j. *Po0.05; **Po0.01; ***Po0.001, all quantified data are presented as mean and s.e.m. ANOVA, analysis
of variance.
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bromodeoxyuridine (BrdU) pulsing inWT and Trib2−/−
mice. DN3 thymocytes of both genotypes had similar
uptake of BrdU after 1 h of pulsing; however, BrdU+
Trib2−/− DN3 thymocytes were significantly increased
after 4 h of pulsing (Figure 4i and j). This demonstrated
that Trib2−/− developing thymocytes had higher cell
division kinetics and more DN3 thymocytes were
available to uptake BrdU while replicating their DNA.
It is noteworthy that TRIB2 loss only affected
thymopoietic recovery but not hematopoietic regen-
eration in BM. On day 14 post 5-FU treatment, blood
cell counts of WT and Trib2−/− mice were restored to
Figure 5 TRIB2 attenuates the leukemia initiation potential of NOTCH1. (a) Kaplan–Meier survival analysis of the lethally
irradiated recipient (CD45.1+) mice transplanted with 5-FU-enriched WT or Trib2−/− BM cells (donor: CD45.2+) transduced with
either MigR1 control or ICN1 transgene. The number (n) of mice analyzed was from three independent experiments. Engraftment
of transduced donor cells (CD45.2+GFP+) (b) and development of T-ALL leukemia (CD4+CD8+) (c) in moribund mice were verified
by flow cytometry analysis. The values in the outlined areas (c: bottom row) are frequency of leukemic cells in the BM of moribund
mice. Leukemic burden was assessed by the spleen to body weight ratio (d) and WBC counts (e) of moribund mice. (f) Leukemic
infiltration was assessed by measurement of the frequency of leukemic cells in various organs of moribund mice. (g) Activation of
MAPK signaling in T-ALL was determined by western blotting for p-Erk, total Erk, p-p38, total p38, p-JNK, JNK1 and β-actin
signals in the leukemic BM (n = 4 per group). Signals shown were developed from triplicate immunoblots. For a, Log-rank test
was used to compare the survival curves. **P = 0.0053, all quantified data are presented as mean and s.e.m. GFP, green
fluorescent protein; WBC, white blood cell.
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normal with no measurable differences detected
(Supplementary Figure S7A and B). However, more
CD4+ and CD8+ T cells were present in the blood of
Trib2−/− mice though these were not statistically sig-
nificant (Supplementary Figure S7C). Both genotypes
had similar BM cellularity and HSPC populations,
including common lymphoid progenitors that are
lymphoid-restricted progenitors [36] (Supplementary
Figure S7D–F). Hence, hematopoiesis in BM was
restored normally in the absence of TRIB2.
TRIB2 loss accelerates T-ALL via defective MAPK
signaling
As TRIB2 appears to negatively regulate the
proliferation of developing thymocytes, the normal
counterpart of T-ALL, we examined the role of TRIB2
in T-cell leukemogenesis using a NOTCH1-induced
T-ALL BM transplantation mouse model [37]. WT
and Trib2−/− BM cells were transduced with an empty
vector control (MigR1) or a retroviral vector encoding
an intracellular Notch1 transgene (ICN1). The cells,
which were CD45.2+, were then transplanted into
lethally irradiated CD45.1+ recipient mice to monitor
the development of T-ALL. All experimental groups
were verified by Trib2 genotyping analysis of the
transplanted moribund mice (Supplementary Figure S8).
Mice transplanted with ICN1-transduced Trib2−/−
donor cells succumbed to T-ALL disease with a shorter
latency (median survival of 43.5 days), whereas mice
transplanted with ICN1-transduced WT donor cells
had a median survival of 63.5 days. Kaplan–Meier
survival analysis for these two groups was significantly
different (Figure 5a), indicating that T-ALL onset
driven by NOTCH1 overexpression was accelerated in
the absence of TRIB2. Green fluorescent protein
expression was used as a marker for transduced donor
cells and analysis showed similar engraftment levels
of transduced WT and Trib2−/− donor cells in the
recipients from all groups across different analyzed
organs (Figure 5b). TRIB2 loss did not alter the
phenotype of murine NOTCH1-induced T-ALL
(Figure 5c). Despite a difference of 20 days for disease
onset, mice that succumbed earlier to Trib2−/− T-ALL
had a similar degree of leukemic burden (Figure 5d and
e) but exhibited a trend of higher organ infiltration of
leukemic cells (Figure 5f) compared with mice that
succumbed to WT T-ALL. We have ruled out that the
T-ALL phenotype is not due to an increase in Trib1
expression, as Trib1 expression levels do not change
upon knockdown of Trib2 in T-ALL or AML cell lines
(Supplementary Figure S9; Supplementary Table S2).
Tribbles family (TRIB1–3) is known to be associated
with MAPK signaling and required for the activation
of ERK, JNK and p38 [38–41]. Western blotting for
MAPK signals in leukemic infiltrated BM samples
showed impaired activation of ERK, JNK and p38
in Trib2−/− T-ALL compared with WT T-ALL
(Figure 5g).
Trib2 expression levels distinguish molecular subtypes of
T-ALL and correlate with MAPK signaling
As TRIB2 loss accelerated T-ALL onset in our
experimental model, we performed gene set enrichment
analysis (GSEA) to compare gene expression profiles of
low and high Trib2 expression from a database
(GSE13159) derived from 174 T-ALL patient samples
(Figure 6a) [42]. GSEA analysis showed these two
groups, defined by Trib2 expression, were of distinct
molecular subtypes of T-ALL (Figure 6b). Low Trib2-
expressing T-ALL group was enriched with gene
set associated with TLX1+ T-ALL (cortical mature
T-ALL), whereas high Trib2-expressing T-ALL group
had upregulation of LYL1+ T-ALL (early immature
T-ALL) gene set [43]. TAL1+ T-ALL gene set was
not enriched in either group. A significant positive
correlation between Trib2 and Lyl1 expressions was
confirmed in an independent T-ALL data set
(GSE33315) [44] (Figure 6c). In our experimental
model, Trib2−/− T-ALL leukemic cells exhibited defi-
ciencies in MAPK signaling. In accordance with this,
using GSEA analysis of low and high Trib2 expressed
human T-ALL groups, MAPK signaling was found to
be upregulated in the high Trib2-expressing T-ALL
group (Figure 6d). Hence, impaired activation of
MAPK signaling in the absence of TRIB2 contributed
to the increased aggressiveness of NOTCH1-induced
murine T-ALL disease that recapitulated the
immunophenotypes of human cortical mature T-ALL.
Our analysis suggests that TRIB2 possesses tumor-
suppressive functions important for T-ALL.
Discussion
Our data provide strong evidence that TRIB2
is a novel regulator of thymopoietic proliferation,
important in the response to stress and the patho-
genesis of T-ALL. We have established a previously
unrecognized role for TRIB2 as a novel regulator
for cellular proliferation of developing thymocytes.
At steady state, Trib2−/− developing thymocytes
proliferated faster and gave rise to more mature
thymocytes. The accelerated proliferation of Trib2−/−
developing thymocytes conferred hypersensitivity to
5-FU-induced cell death. Following genotoxic insult,
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Trib2−/− mice exhibited accelerated thymopoietic
recovery due to expansion of c-Kit− DN1 progenitors
and high cell division kinetics of developing
thymocytes. In the absence of TRIB2, NOTCH1 is
more potent in driving T-ALL initiation and the
increased aggressiveness of Trib2−/− T-ALL was
enhanced by impaired activation of MAPK signaling.
Human T-ALL can be distinguished based on Trib2
expression levels and, in accordance with our
experimental data, correlate with MAPK signaling in
high Trib2-expressing T-ALLs.
Here we show TRIB2 as the first member of the
mammalian Tribbles family to have a proliferative
role in the context of developing thymocytes during
T-cell development. TRIB1 was reported previously to
negatively regulate proliferation of human aortic
smooth muscle cells in vitro via interaction withMKK4
[45]. TRIB2 regulates cell cycle entry/exit and hence the
cell division kinetics of developing thymocytes. We
found that the dysregulated proliferation of Trib2−/−
developing thymocytes does not affect Tcrb rearran-
gement, a key event in early T-cell differentiation.
Figure 6 Trib2 levels distinguish molecular subtypes of human T-ALL and associate with MAPK signaling. (a) GSEA was
performed to compare human T-ALL samples from GSE13159 data set [42] that expressed low and high Trib2 (n = 26 per group)
for enrichment of human T-ALL molecular subtypes (b) and canonical pathways (d). NES, normalized enrichment score; Nom,
nominal. (c) Correlation between Trib2 (average of 202478_at and 202479_s_at) and Lyl1 (210044_s_at) expressions were
examined in 84 human T-ALL samples from GSE33315 data set [44]. For c, Pearson correlation test was used to examination
association between Trib2 and Lyl1 expressions.
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Furthermore, loss of TRIB2 did not affect terminal
maturation of developing thymocytes. Intriguingly, the
increased proliferation of developing thymocytes, in
the absence of TRIB2, does not affect the percentage of
peripheral T cells. Previous literature has shown that
mice overexpressing CD69 have increased thymic SP
subsets but a reduction in the number of T cells in the
peripheral lymphoid organs [46]. Our data suggest that
TRIB2 may impact on thymic selection (DPsm to
CD69+ DP transition) or thymic T-cell export. It is also
likely that TRIB2 has a distinct role in mature
T-cell biology and function because Trib2 expression
distinguishes CD4+ from CD8+ peripheral T-cells [23].
This could be further explored using appropriate
infection and immunization models.
Thymopoietic recovery is critical to replenish the
T-cell repertoire in order to reconstitute cellular
immunity due to T-cell depletion in the clinical setting.
At steady state, human T-cell repertoire is established
during early childhood as removal of the thymus in
children after 6 months of age does not cause overt
immunodeficiency [47]. However, many medical con-
ditions such as chemo- and irradiation therapy, infec-
tion and graft versus host disease can cause T-cell
depletion, thymus insult and thus impaired T-cell
immunity in patients [48]. Our study showed that
TRIB2 limits the thymopoietic recovery after 5-FU
injury. The reason underlying this is unclear but tight
regulation of thymopoietic restoration has been pro-
posed to prevent adverse consequences such as leu-
kemic transformation of T-cells or autoimmunity [48].
We showed that TRIB2 functions to suppress T-cell
leukemogenesis induced by NOTCH1 overexpression.
A role for TRIB2 in T-ALL maintenance was
demonstrated by Sanda et al [13] , as knockdown of
Trib2 in a panel of TAL1-positive human T-ALL cell
lines induced apoptosis and inhibited cell growth. This
appears to be consistent with the role of TRIB2 in other
solid [49–51] and hematological [9] malignancies that
overexpression of TRIB2 confers growth and survival
advantages to tumor cells. However, we provide strong
evidence that TRIB2 has opposing roles in the
initiation and potency of T-ALL. In the absence of
TRIB2, the latency of NOTCH1-induced murine
T-ALL was shortened significantly. We previously
reported elevated Trib2 levels in a cohort of pediatric
T-ALLs that contain NOTCH1/FBXW7 mutations
compared withWT T-ALLs [11]. However, T-ALL is a
heterogeneous disease and can be classified into
different molecular subtypes, although aberrant
NOTCH1 signaling is the unifying feature in all the
subtypes. Hence, we performed GSEA analysis in this
study to show Trib2 is high in early immature (LYL1+)
T-ALLs that are arrested at the DN stage of thymocyte
development and show a transcriptional program
related to HSCs and myeloid progenitors [44, 52]. In
turn, Trib2 is low in TLX1+ human T-ALLs that have a
mature cortical DP phenotype where the transformed
cells have committed to the T-cell lineage [43]. We
propose that the role of TRIB2 in different subtypes of
human T-ALL depends on the stage at which thymic
progenitors undergo malignant transformation, and if
they have committed to T-cell lineage.
There is a strong correlation with Trib2 and MAPK
signaling in human T-ALL as shown by GSEA
analysis. Previously, the activation of ERK and p38
was shown to inversely correlate with aggressiveness of
T-ALL in a model of T-ALL cell dormancy [53].
Furthermore, drug treatment of established human
T-ALL cell lines was shown to induce cell death via
activation of p38 and JNK [54–56]. Thus, activation of
MAPK signaling appears to be a limiting factor, at
least, in the context of T-ALL. TRIB family members
act as scaffold proteins for the binding of MAPK sig-
naling complexes and hence modulate their activity.
All TRIB family members have the conserved MEK1-
binding motif and have been shown to interact with
MEK1 [38]. In human T-ALLs, upregulation of
ERK1/2 signaling was found in 38% of T-ALL patients
[57] and MEK/ERK can be activated due to RAS
mutations, found in ~ 10% of T-ALL patients [58].
Targeting of MEK/ERK signaling by MEK inhibition
was shown to be effective in treating KRAS-mutated
T-ALL in a murine model [59]. The upregulation of
MAPK signaling in specific subtypes of T-ALL has not
been studied and remains unclear. Here we show that
Trib2 expression is high in LYL1+ immature T-ALLs
enriched with MAPK signaling, and our experimental
data show defective MAPK signaling in the absence of
TRIB2. Thus, it appears that TRIB2 functions to
control T-ALL via MAPK modulation.
We and others [7, 60] have shown that Trib2 is a
myeloid oncogene when overexpressed in a murine BM
transplant model. Here loss of TRIB2 potentiated
murine T-ALL induced by a T-cell oncogene. Given
that Trib2 is expressed highest in normal T cells [19],
it is not surprising that overexpression of Trib2 does
not drive T-ALL in the BM transplant model, and our
data would suggest that TRIB2 functions to suppress
T-ALL. Our data provide insight into the under-
standing of the opposing leukemogenic roles of TRIB2
in myeloid and lymphoid leukemia. However, the
mechanisms that underlie whether TRIB2 acts as an
oncogene or tumor suppressor are not well understood.
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It may be linked to its function in cell proliferation and
MAPK pathway modulation, which could be cell
context specific. Anti- and pro-proliferative effects
connected with MAPK signaling and TRIB1 have
been previously demonstrated in different cell contexts
[38, 45].
To conclude, our studies have shown that TRIB2 is a
novel regulator for the cellular proliferation of devel-
oping thymocytes, and the response to genotoxic and
oncogenic stress. Although the loss of TRIB2 resulted
in hypersensitivity to genotoxic stress, thymocytes
recovered faster due to the inherent increased
proliferation in the absence of TRIB2. These char-
acteristics however are pro-oncogenic, as accelerated
T-ALL was observed in the absence of TRIB2. Our
findings provide a novel link between proliferative
stress and TRIB2 in developing thymocytes, and may
prove relevant for clinical practice in hematology and
oncology.
Materials and Methods
Antibodies
The following antibodies, from BioLegend (San Diego, CA,
USA) and eBioscience (San Diego, CA, USA), were used to
stain cells for flow cytometry analysis: anti-B220 (RA3–6B2),
anti-BrdU (BU20A), anti-CD3 (17A2), anti-CD4 (RM4–5 and
GK1.5), anti-CD8α (53-6.7), anti-CD11b (M1/70), anti-CD11c
(N418), anti-CD16/CD32 (93), anti-CD19 (eBio1D3), anti-
CD25 (PC61.5), anti-CD34 (RAM34), anti-CD44 (IM7), anti-
CD45.2 (104), anti-CD48 (HM48-1), anti-CD71 (R17217) anti-
CD150 (TC15-12F12.2), anti-c-Kit (2B8), anti-Gr-1 (RB6–
8C5), anti-IL-7Rα (A7R34), anti-Ki-67 (SolA15), anti-NK1.1
(PK136), anti-Sca-1 (D7) and anti-Ter119 (TER-119).
The following antibodies were used for western blotting:
anti-p38 (D13E1), anti-phospho-p38 (D3F9), anti-p44/42
(137F5), anti-phospho-p44/42 (D13.14.4E), anti-JNK1 (2C6),
anti-phopho-JNK and anti-β-actin (AC-15). Antibodies used
to immunoblot MAPK signaling were from Cell Signaling
Technology (Danvers, MA, USA) and anti-β-actin antibody
was from Sigma-Aldrich (St Louis, MO, USA).
Mice
Trib2−/− (B6; 129S5-Trib2tm1Lex) mice, backcrossed onto
C57BL/6, were bred and housed in the biological service unit of
the University of Glasgow. Mice (B6.SJL-Ptprca Pepcb/ BoyJ)
used in BM transplantation as recipients were bred and
housed in the Beatson Biological Service and Research Units.
Age-matched (6–14 weeks old) mice of both genders were used
for comparison between WT and Trib2−/− genotypes.
Blood cell counts
Mice were sacrificed by carbon dioxide inhalation and blood
was subsequently collected by cardiac puncture. Collected blood
was analyzed by Hemavet 950 (Drew Scientific, Miami Lakes,
FL, USA) to generate complete blood counts and white blood
cell differential counts.
Cell preparation, surface staining and flow cytometry
Pelvises, femurs and tibias collected from euthanized mice were
dissected free of muscle tissues and tendons. The bones were
crushed in 2% fetal bovine serum supplemented phosphate-
buffered saline (PBS) solution using a mortar and pestle. The
resulting cell suspension was filtered through a cell strainer. Thy-
mus was isolated and grinded directly onto a cell strainer
to generate single-cell suspensions. Red blood cell in blood,
BM and thymus cell suspensions were lysed by homemade
Ammonium-Chloride-Potassium Lysing Buffer containing 10 mM
KHCO3, 150 mM NH4Cl and 0.1 mM EDTA. Live-cell count for
BM and thymus was then performed by trypan blue exclusion.
Lineage antibody cocktail for BM cell surface staining
included anti-CD3, anti-CD4, anti-CD8, anti-B220, anti-
CD11b, anti-Gr-1 and anti-Ter119 antibodies. For thymus, non-
T-lineage antibody cocktail included anti-CD11c, anti-B220,
anti-Gr-1, anti-NK1.1 and anti-Ter119 antibodies. Antibodies
used for flow cytometry were conjugated either with single
fluorochrome or with biotin and revealed by fluorochrome-
labeled streptavidin. All the cell populations identified by flow
cytometry were defined in the related figure legends.
Unless indicated otherwise, antibody staining and washing of
single-cell suspensions were done in 2% fetal bovine serum sup-
plemented PBS solution. UltraComp eBeads (eBioscience) was
used to prepare single-color compensation controls in multicolor
flow cytometry experiments. Flow cytometry was performed using
BD FACSCanto II system, equipped with blue, red and violet
lasers (BD Biosciences, San Jose, CA, USA). Aggregates were
excluded by forward scatter (FSC) height versus area signals. The
singlet population was then gated by FSC area versus side scatter-
area signals to exclude dead cells and debris. Whenever possible,
dead cells were also excluded by 40, 6-diamidino-2-phenylindole or
propidium iodide staining. FlowJo (Tree Star, Ashland, OR,
USA), was used to analyze flow cytometry data. Fluorescence
Minus One controls were used to facilitate gating as appropriate.
In vivo 5-FU treatment
On the drug administration day, mice were weighed to
calculate the weight-adjusted dosage, as indicated in the related
figure legends, and FU 50 mg ml− 1 Solution (Accord Healthcare
Limited, North Harrow, Middlesex, UK) was pre-diluted with
PBS solution and was administered by intraperitoneal injection.
Apoptosis assay
Thymus was collected from euthanized mice after the indicated
period of 5-FU treatment and single-cell suspension was prepared
as described above. Cells were stained with Annexin V-fluorescein
isothiocyanate and 4’, 6-diamidino-2-phenylindole in Hank’s
balanced salt solution, and analyzed by flow cytometry.
Detection of endogenous Tcrb rearrangements
Total thymocytes were digested overnight with proteinase K
in published lysis buffer [61] at 56 °C. Samples were then heated
at 95 °C for 30 min to inactivate proteinase K. DNA was
purified further by phenol extraction and ethanol precipitation.
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V(D)J rearrangements of the Tcrb locus were amplified by
FastStart High Fidelity PCR system (Roche, Indianapolis, IN,
USA), with 25 ng of DNA input, using published primers [62].
Primer sequences and the annealing temperatures for each
amplification were listed in Supplementary Table S3. PCR
products were separated on 1.5% agarose gel, detected by
SafeView Nucleic Acid Stain (NBS Biologicals, Huntingdon,
Cambridgeshire, UK), and imaged using ChemiDoc XRS sys-
tem (Bio-Rad, Hercules, CA, USA).
Intracellular staining of Ki-67 and cell cycle analysis
Thymocytes were stained with surface markers to allow
subset identification, and then fixed in 4% weight/volume
paraformaldehyde-PBS solution for 20 min at room tempera-
ture, permeabilized in 0.1% (weight/volume) saponin-PBS
solution for 15 min at room temperature, followed by staining
with anti-Ki-67 antibody in the permeabilization solution and
analyzed by flow cytometry.
To distinguish resting (G0) from active (G1–S/G2/M) cell
cycle, surface stained thymocytes were fixed and permeabilized
by using BD Cytofix/Cytoperm Kit (BD Biosciences), followed
by staining with anti-Ki-67 antibody and DNA selective
Vybrant DyeCycle Violet Stain (Life Technologies, Eugene,
OR, USA) and analyzed by flow cytometry.
In vivo BrdU pulsing and detection of incorporated BrdU
On day 14 post 5-FU treatment, mice were pulsed with 1 mg
BrdU-labeling reagent (Invitrogen, Camarillo, CA, USA), by
intraperitoneal injection, for 1 or 4 h. Thymus was collected from
euthanized mice and single-cell suspension was prepared. Surface-
stained thymocytes were fixed in BD Cytofix/Cytoperm Buffer for
30 min on ice and stored at −80 °C for overnight in 10% dime-
thylsulfoxide supplemented fetal bovine serum to permeabilize the
nuclear membrane. Cells were then thawed at 37 °C, fixed with BD
Cytofix/Cytoperm Buffer for an additional 10 min on ice and
treated with DNase I (30 μl per 1×106 cells) from STEMCELL
Technologies (Vancouver, BC, Canada) for 1 h at 37 °C. Cells were
stained with anti-BrdU antibody and Vybrant DyeCycle Violet
Stain (Life Technologies) in BD Perm/Wash Buffer (San Jose, CA,
USA) and analyzed by flow cytometry.
Bone marrow transduction and transplantation
Retroviral transduction of WT and Trib2−/− BM cells,
and subsequent transfer of these cells into lethally irradiated
recipients (B6.SJL) were performed as described previously [7].
In brief, BM cells were collected from 6–8-week-old mice
4 days after administration of 5-FU (250 mg kg–1, intraper-
itoneally) and retrovirally transduced ex vivo, with MigR1 or
MigR1-ICN1, in the presence of interleukin (IL)-3
(10 ng ml− 1), IL-6 (10 ng ml− 1) and stem cell factor
(100 ng ml− 1). Retroviral supernatants for MigR1 and MigR1-
ICN1 were generated by transient transfection of 293T cells
(together with pCMV-Gag-Pol packaging vector and
pCMV-VSV-G envelope vector) and titered with 3T3 cell as
previously described [10]. MigR1 and MigR1-ICN1 retroviral
supernatants with equal titers were used to ensure similar
transduction efficiency across three independent transplant
experiments. Cells (0.25–0.5 × 106) were then injected
intravenously into lethally irradiated (2 × 4.25 grays fractio-
nated doses were given 3 h apart) recipients. Mice were mon-
itored by periodic tail vein bleedings 3 weeks after
transplantation. Mice were sacrificed when they showed any of
the following symptoms of disease: severe cachexia, lethargy,
white blood cell count 420 × 106 cells per ml and hunching.
Healthy controls were sacrificed at the end of experiment when
all mice in the test groups succumbed to disease.
GSEA analysis
Gene expression profiles of T-ALL and healthy BM samples
from GSE13159 data set [42] were downloaded from the
Leukemia Gene Atlas platform [63]. On the basis of 202478_at
feature, Trib2 expression of low Trib2 T-ALL group ranged
from 3.602 to 5.370, whereas high Trib2 T-ALL group ranged
from 8.811 to 11.103. The mean value of Trib2 for healthy BM
samples (n = 73) was 6.172. GSEA [64] was performed using the
default settings. Gene sets from the Molecular Signatures
Database v5.0 of GSEA (Broad Institute of MIT and Harvard,
Cambridge, MA, USA) were used. These included the 1330 gene
sets in C2: CP collection for canonical pathways and the three
gene sets in C2: CGP collection (M4175, M2059 andM1007) for
T-ALL molecular subtypes.
Western blotting
Total BM cells collected from euthanized mice were lysed in
homemade Radio-Immunoprecipitation Assay buffer (50 mM
Tris buffer (pH7.4), 150 mM NaCl, 0.5% igepal CA 630, 0.25%
sodium deoxycholate and 1 mM EDTA). Protein lysates were
resolved by sodium dodecylsulfate polyacrylamide gel electro-
phoresis using 12% gels and transferred to 0.45-μm nitrocellu-
lose membranes. The membranes were probed with primary
antibodies followed by horseradish peroxidase-conjugated sec-
ondary antibodies. Stripping buffer (Thermo Scientific, Rock-
ford, IL, USA) was used as appropriate for secondary probing.
Statistics
GraphPad Prism (version 5.03; La Jolla, CA, USA) was used
for statistical analysis and graphing. An unpaired, two-tailed,
Student’s t-test was applied for comparison of two groups. For
analysis of multiple groups between WT and Trib2−/− genotypes,
two-way analysis of variance with Bonferroni post tests was
applied. Log-rank test was applied for survival curve compar-
ison. Pearson correlation test was applied to examine associa-
tion between Trib2 and Lyl1 expressions of T-ALL samples
from GSE33315 data set [44]. This data set was downloaded
from Gene Expression Omnibus and Robust Multichip Average
method was used for data normalization. D’Agostino-Pearson
omnibus test confirmed the T-ALL samples had normal
distributions of Trib2 and Lyl1 values. Statistical significance of
differences was attained when P-value o0.05 and was indicated
in the related graphs.
Study approval
All mouse experiments were approved by UK Animal
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Office project license (Animal (Scientific Procedures) Act 1986)
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